Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge J Castillo

Showing results (261-270 of 343) with videos related to

Pageof 35
Sort By:
Blood Advances|January 18, 2024
Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemiaKris Richardson, Jorge J Castillo, Shayna R Sarosiek, et al.
Leukemia Research|June 18, 2026
Real-world outcomes of plasmablastic lymphoma: Treatment approaches and survival outcomes in the PLASMABLAT-001 cohortHumberto Martinez-Cordero, Paola Spirko, Irma Karen Pellon, et al.
Blood|December 8, 2018
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter studyJorge J Castillo, Gilad Itchaki, Jonas Paludo, et al.
Blood|July 20, 2016
Treatment recommendations from the Eighth International Workshop on Waldenström's MacroglobulinemiaVéronique Leblond, Efstathios Kastritis, Ranjana Advani, et al.
Blood Advances|November 30, 2021
Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemiaSabrin Tahri, Tarek H Mouhieddine, Robert Redd, et al.
Plos One|October 5, 2018
Profiling of circulating exosomal miRNAs in patients with Waldenström MacroglobulinemiaJuliette M Bouyssou, Chia-Jen Liu, Mark Bustoros, et al.
The Lancet. Haematology|October 22, 2020
Consensus treatment recommendations from the tenth International Workshop for Waldenström MacroglobulinaemiaJorge J Castillo, Ranjana H Advani, Andrew R Branagan, et al.
Haematologica|June 24, 2021
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapyJoshua N Gustine, Shayna Sarosiek, Catherine A Flynn, et al.
Leukemia & Lymphoma|July 24, 2018
Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 casesArtur Jurczyszyn, Julio Davila, K Martin Kortüm, et al.
British Journal of Haematology|July 4, 2019
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinibJorge J Castillo, Lian Xu, Joshua N Gustine, et al.
Pageof 35

Showing results (261-270 of 343) with videos related to

Sort By:
Pageof 35
Blood Advances|January 18, 2024
Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemiaKris Richardson, Jorge J Castillo, Shayna R Sarosiek, et al.
Leukemia Research|June 18, 2026
Real-world outcomes of plasmablastic lymphoma: Treatment approaches and survival outcomes in the PLASMABLAT-001 cohortHumberto Martinez-Cordero, Paola Spirko, Irma Karen Pellon, et al.
Blood|December 8, 2018
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter studyJorge J Castillo, Gilad Itchaki, Jonas Paludo, et al.
Blood|July 20, 2016
Treatment recommendations from the Eighth International Workshop on Waldenström's MacroglobulinemiaVéronique Leblond, Efstathios Kastritis, Ranjana Advani, et al.
Blood Advances|November 30, 2021
Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemiaSabrin Tahri, Tarek H Mouhieddine, Robert Redd, et al.
Plos One|October 5, 2018
Profiling of circulating exosomal miRNAs in patients with Waldenström MacroglobulinemiaJuliette M Bouyssou, Chia-Jen Liu, Mark Bustoros, et al.
The Lancet. Haematology|October 22, 2020
Consensus treatment recommendations from the tenth International Workshop for Waldenström MacroglobulinaemiaJorge J Castillo, Ranjana H Advani, Andrew R Branagan, et al.
Haematologica|June 24, 2021
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapyJoshua N Gustine, Shayna Sarosiek, Catherine A Flynn, et al.
Leukemia & Lymphoma|July 24, 2018
Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 casesArtur Jurczyszyn, Julio Davila, K Martin Kortüm, et al.
British Journal of Haematology|July 4, 2019
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinibJorge J Castillo, Lian Xu, Joshua N Gustine, et al.
Pageof 35